Syros Pharmaceuticals, Inc. Common Stock
SYRS
SYRS was delisted on the 19th of March, 2025.
64 hedge funds and large institutions have $266M invested in Syros Pharmaceuticals, Inc. Common Stock in 2020 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 22 increasing their positions, 22 reducing their positions, and 17 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 22
9% less funds holding
Funds holding: 70 → 64 (-6)
9% less capital invested
Capital invested by funds: $291M → $266M (-$25.1M)
29% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$15.4M |
| 2 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$5.57M |
| 3 |
AG
Artal Group
Luxembourg
|
+$3.43M |
| 4 |
PCM
Portolan Capital Management
Boston,
Massachusetts
|
+$1.26M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$974K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$3.63M |
| 2 |
AVM
Arch Venture Management
Chicago,
Illinois
|
-$1.7M |
| 3 |
Renaissance Technologies
New York
|
-$892K |
| 4 |
JP Morgan Chase
New York
|
-$438K |
| 5 |
D.E. Shaw & Co
New York
|
-$422K |
SYRS Hedge Fund Activity: Q1 2020 in Review
64 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in Syros Pharmaceuticals, Inc. Common Stock (SYRS) for Q1 2020, worth a combined $266M — down 8.6% from $291M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of SYRS and 12 opened new positions — a net loss of 5 holders — while 22 trimmed existing stakes and 22 added.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $15.4M. The largest seller was Millennium Management, exiting entirely with an estimated $3.63M sold.
- 64 institutional investors held Syros Pharmaceuticals, Inc. Common Stock (SYRS) as of Q1 2020, down from 70 in Q4 2019.
- Funds reported $266M of Syros Pharmaceuticals, Inc. Common Stock stock for Q1 2020, down 8.6% quarter-over-quarter.
- 12 funds opened new Syros Pharmaceuticals, Inc. Common Stock positions in Q1 2020 and 17 closed out, a net change of -5 holders.
- The largest Syros Pharmaceuticals, Inc. Common Stock buyer in Q1 2020 was Point72 Asset Management, an estimated $15.4M added.
- The largest Syros Pharmaceuticals, Inc. Common Stock seller in Q1 2020 was Millennium Management, an estimated $3.63M sold.
Based on aggregated 13F filings for Q1 2020.